SCHEMBL9953672

SCHEMBL9953672

COc1cc(-c2ccc(Nc3ccc(C)cc3C(=O)O)c(OC)c2)ccc1Nc1ccc(C)cc1C(=O)O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.72
APAF1 O14727 1/20 0.72
RECQL P46063 1/20 0.72
CASP6 P55212 1/20 0.72
CACNA1B Q00975 1/20 0.72
APBA1 Q02410 1/20 0.72
MCL1 Q07820 1/20 0.72
CASP8 Q14790 1/20 0.72
ALDH1A1 P00352 2/20 0.55
HPGD P15428 1/20 0.55
AKR1C3 P42330 2/20 0.53
AKR1C2 P52895 2/20 0.53
FABP3 P05413 2/20 0.51
FABP4 P15090 2/20 0.51
ACLY P53396 1/20 0.51
DHODH Q02127 5/20 0.50
MAPT P10636 1/20 0.48
CDC25B P30305 1/20 0.48
HTT P42858 1/20 0.48
NPC1 O15118 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9953717 0.94 KDM4E (0.85) KDM4EAPAF1RECQLCASP6CACNA1B
SCHEMBL1720516 0.84 KDM4E (1.00) KDM4EAPAF1RECQLCASP6CACNA1B
SCHEMBL29441241 0.84 KDM4E (1.00) KDM4EAPAF1RECQLCASP6CACNA1B
SCHEMBL30294462 0.83 KCNMA1 (0.56) KDM4EAPAF1RECQLCASP6CACNA1B
SCHEMBL30294465 0.83 KCNMA1 (0.56) KDM4EAPAF1RECQLCASP6CACNA1B
SCHEMBL22853477 0.83 KCNMA1 (0.56) KDM4EAPAF1RECQLCASP6CACNA1B
SCHEMBL10075557 0.83 KDM4E (0.68) KDM4EAPAF1RECQLCASP6CACNA1B
SCHEMBL22720143 0.81 MEN1 (0.63) HPGDAKR1C3AKR1C2FABP3FABP4
SCHEMBL91954 0.79 CSNK2A1 (0.59) KDM4EALDH1A1HPGDMAPTNPC1
SCHEMBL30100430 0.79 CSNK2A1 (0.59) KDM4EALDH1A1HPGDMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9351971-B2 Substituted 2,2′-biphenazines for treating diseases EUTROPICS PHARMACEUTICALS, INC. (US) 2016-05-31 US disclosed
US-9351971-B2 Substituted 2,2′-biphenazines for treating diseases EUTROPICS PHARMACEUTICALS, INC. (US) 2016-05-31 US disclosed
US-9351971-B2 Substituted 2,2′-biphenazines for treating diseases EUTROPICS PHARMACEUTICALS, INC. (US) 2016-05-31 US disclosed
US-20150216862-A1 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS THERAPEUTICS, INC. 2015-08-06 US disclosed
US-20150216862-A1 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS THERAPEUTICS, INC. 2015-08-06 US disclosed
US-20150216862-A1 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS THERAPEUTICS, INC. 2015-08-06 US disclosed
US-8987271-B2 2,2′-biphenazine compounds and methods useful for treating disease EUTROPICS PHARMACEUTICALS, INC. (US) 2015-03-24 US disclosed
US-8987271-B2 2,2′-biphenazine compounds and methods useful for treating disease EUTROPICS PHARMACEUTICALS, INC. (US) 2015-03-24 US disclosed
US-8987271-B2 2,2′-biphenazine compounds and methods useful for treating disease EUTROPICS PHARMACEUTICALS, INC. (US) 2015-03-24 US disclosed
EP-2655334-A1 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES Eutropics Pharmaceuticals, Inc. (US) 2013-10-30 EP disclosed
US-20120225851-A1 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS PHARMACEUTICALS, INC. (US) 2012-09-06 US disclosed
US-20120225851-A1 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS PHARMACEUTICALS, INC. (US) 2012-09-06 US disclosed
US-20120225851-A1 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS PHARMACEUTICALS, INC. (US) 2012-09-06 US disclosed
WO-2012088438-A1 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS PHARMACEUTICALS, INC. (US) 2012-06-28 WO disclosed
WO-2012088438-A1 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS PHARMACEUTICALS, INC. (US) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225851-A1 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES MCL1, BCL3, BCL9 KDM4E 1427/4885APAF1 111/4885RECQL 627/4885
US-20150216862-A1 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES MCL1, BCL3, BCL2L1 KDM4E 709/4885APAF1 60/4885RECQL 782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.